Literature DB >> 21119090

Active surveillance for prostate cancer.

Ian M Thompson, Laurence Klotz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21119090      PMCID： PMC5034724          DOI： 10.1001/jama.2010.1761

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

1.  Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study.

Authors:  Benny Holmström; Erik Holmberg; Lars Egevad; Jan Adolfsson; Jan-Erik Johansson; Jonas Hugosson; Pär Stattin
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

2.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.

Authors:  Isaac J Powell; Cathryn H Bock; Julie J Ruterbusch; Wael Sakr
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Authors:  Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Susan T Stewart; Vibha Bhatnagar; Christopher J Sweeney; James E Stahl; Pamela M McMahon
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

5.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

6.  In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.

Authors:  Lorenzo Drago; Lucia Nicola; Roberto Mattina; Elena De Vecchi
Journal:  BMC Microbiol       Date:  2010-04-21       Impact factor: 3.605

7.  Rethinking screening for breast cancer and prostate cancer.

Authors:  Laura Esserman; Yiwey Shieh; Ian Thompson
Journal:  JAMA       Date:  2009-10-21       Impact factor: 56.272

8.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544
  8 in total
  7 in total

1.  Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk.

Authors:  Guang Xu; Jian Wu; Ming-Hua Yao; Xu-Dong Yao; Bo Peng; Qing Wei; Hui-Xiong Xu; Rong Wu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

3.  Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.

Authors:  Hebert Alberto Vargas; Oguz Akin; Asim Afaq; Debra Goldman; Junting Zheng; Chaya S Moskowitz; Amita Shukla-Dave; James Eastham; Peter Scardino; Hedvig Hricak
Journal:  J Urol       Date:  2012-09-25       Impact factor: 7.450

4.  Modeling potential time to event data with competing risks.

Authors:  Liang Li; Bo Hu; Michael W Kattan
Journal:  Lifetime Data Anal       Date:  2013-09-24       Impact factor: 1.588

5.  Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.

Authors:  Yunee Kim; Jouhyun Jeon; Salvador Mejia; Cindy Q Yao; Vladimir Ignatchenko; Julius O Nyalwidhe; Anthony O Gramolini; Raymond S Lance; Dean A Troyer; Richard R Drake; Paul C Boutros; O John Semmes; Thomas Kislinger
Journal:  Nat Commun       Date:  2016-06-28       Impact factor: 14.919

6.  Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial.

Authors:  Daniel A Galvão; Dickon Hayne; Mark Frydenberg; Suzanne K Chambers; Dennis R Taaffe; Nigel Spry; Paul A Scuffham; Robert S Ware; Nicolas H Hart; Robert U Newton
Journal:  BMJ Open       Date:  2018-04-20       Impact factor: 2.692

7.  Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.

Authors:  Antti Rannikko; Mare Leht; Tuomas Mirtti; Anu Kenttämies; Teemu Tolonen; Irina Rinta-Kiikka; Tuomas P Kilpeläinen; Kari Natunen; Hans Lilja; Terho Lehtimäki; Jani Raitanen; Paula Kujala; Johanna Ronkainen; Mika Matikainen; Anssi Petas; Kimmo Taari; Teuvo Tammela; Anssi Auvinen
Journal:  BJU Int       Date:  2022-01-08       Impact factor: 5.969
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.